Warning! GuruFocus has detected 4 Medium warning signs with LLY. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for LLY (Eli Lilly and Co) from 1990 to May 10 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Eli Lilly and stock (LLY) PE ratio as of May 10 2021 is 29.61. More Details
Eli Lilly and PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Eli Lilly and PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Traded in other countries
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.